Drug Trial Radar · NCT00081770
Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)
Last checked: Nov 20, 2026Latest source record: Apr 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,469
Actual
Start
Mar 2004
Primary completion
Nov 2007
Study completion Nov 2007
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 22, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PegIntron 1.5 µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2) PegIntron 1µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3) PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day.
Conditions
- Hepatitis C, Chronic
Interventions
PegIntron (peginterferon alfa-2b; SCH 54031)Biological
1.5 ug/kg/week subcutaneously (SC) for 48 weeks
PegIntron (peginterferon alfa-2b; SCH 54031)Biological
1.0 ug/kg/week SC for 48 weeks
REBETOL (ribavirin; SCH 18908)Drug
weight based dose 800-1400 mg/day orally (PO) for 48 weeks
PEGASYS (peginterferon alfa-2a)Biological
180 ug/week SC administered for 48 weeks
COPEGUS (ribavirin)Drug
1000-1200 mg/day PO for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained Virologic Response (SVR) RateTime frame: Assessed at the end of a 24-week post-treatment follow-up
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.